Latin America Antidiabetics Market, 2026-2033
- Pharmaceuticals
- Metabolic Disorders Treatment
- antidiabetics market
- Metabolic Disorders Treatment
Global Market
Related Markets
Ask Prism AI about the antidiabetics market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
Latin America antidiabetics market highlights
- The Latin America antidiabetics market generated a revenue of USD 6,668.9 million in 2025.
- The market is expected to grow at a CAGR of 10.6% from 2026 to 2033.
- In terms of segment, glp-1 receptor agonists was the largest revenue generating drug class in 2025.
- GLP-1 Receptor Agonists is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
Latin America data book summary
| Market revenue in 2025 | USD 6,668.9 million |
| Market revenue in 2033 | USD 15,258.2 million |
| Growth rate | 10.6% (CAGR from 2026 to 2033) |
| Largest segment | Glp-1 receptor agonists |
| Fastest growing segment | GLP-1 Receptor Agonists |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors |
| Key market players worldwide | AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Boehringer Ingelheim, Bristol-Myers Squibb Co, Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG ADR |
Other key industry trends
- In terms of revenue, Latin America region accounted for 6.4% of the global antidiabetics market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 32,717.1 million by 2033.
The Latin American antidiabetics market is gaining traction, with the region recognized as a promising area for industry expansion.
A significant portion of the population is entering older age groups, which is associated with a higher risk of diabetes. Increasing healthcare expenditure, coupled with efforts to improve access to chronic disease treatments, supports regional market growth.
Local governments are working on strengthening health systems and expanding access to antidiabetic drugs and services.
No credit card required*
Publish Date: Apr 14, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antidiabetics Market
Antidiabetics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
Latin America antidiabetics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Antidiabetics Market will help companies and investors design strategic landscapes.
Glp-1 Receptor Agonists was the largest segment with a revenue share of 58.13% in 2025.
Horizon Databook has segmented the Latin America antidiabetics market based on insulin, glp-1 receptor agonists, dpp- 4 inhibitors, sglt2 inhibitors covering the revenue growth of each sub-segment from 2021 to 2033.
The Latin American antidiabetics market is gaining traction, with the region recognized as a promising area for industry expansion.
A significant portion of the population is entering older age groups, which is associated with a higher risk of diabetes. Increasing healthcare expenditure, coupled with efforts to improve access to chronic disease treatments, supports regional market growth.
Local governments are working on strengthening health systems and expanding access to antidiabetic drugs and services.
- Latin America Antidiabetics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Insulin
- GLP-1 Receptor Agonists
- DPP- 4 Inhibitors
- SGLT2 Inhibitors
- Others
- Latin America Antidiabetics Market Diabetes Type Outlook (Revenue, USD Million , 2021-2033)
- Type 1
- Type 2
- Latin America Antidiabetics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Latin America Antidiabetics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Subcutaneous
- Intravenous
Reasons to subscribe to antidiabetics market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of antidiabetics market databook
- Our clientele includes a mix of antidiabetics market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America antidiabetics market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America antidiabetics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Latin America Antidiabetics Market, 2021-2033 (US$M)
Latin America antidiabetics market statistics, by drug class, 2021-2033 (US$M)
